– Revenue of $1,023.8 Million Exceeds Guidance –

– Company Reports GAAP Diluted EPS of $0.86; Non-GAAP Diluted EPS of $1.08 Exceeds Guidance –

– In Fourth Quarter, Company Remains on Track for Solid Revenue Growth and Faster Non-GAAP EPS Growth –

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 28, 2025.

“We are pleased to have delivered revenue and non-GAAP earnings growth in the third quarter that exceeded our guidance ranges,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “And we made great progress toward returning to better top- and bottom-line growth in the fourth quarter, driven by the continued rebound of our Breast Health business and solid performances by our other divisions.”

Recent Highlights

• Revenue of $1,023.8 million increased 1.2% for the quarter, or 0.4% in constant currency. This compares to the guidance range of $1,000 to $1,010 million that the Company provided in early May.
  • Total organic revenue excluding COVID-19, the divested blood screening and SSI businesses, and the acquired Endomagnetics and Gynesonics businesses decreased (0.8%), or (1.7%) on a constant currency basis.
• GAAP diluted EPS of $0.86 for the quarter increased 4.9%. Non-GAAP EPS of $1.08 increased 1.9% and exceeded the high-end of the guidance range of $1.04 to $1.07 that the Company provided in early May.
• Diagnostics revenue of $448.9 million increased 1.8%, or 0.9% in constant currency, primarily driven by higher molecular diagnostics sales, partially offset by lower sales of COVID-19 assays.
  • Excluding COVID-19 revenue, organic diagnostics sales grew 3.9%, or 2.9% on a constant currency basis.
  • Molecular diagnostics revenue increased 3.2%, or 2.4% in constant currency, primarily driven by higher sales of the Company’s BV CV/TV and Panther Fusion assays.
  • Excluding COVID-19 revenue, molecular diagnostics revenue grew 6.0%, or 5.2% on a constant currency basis. This included 7.3% growth in the United States.
• Breast Health revenue of $365.2 million decreased (5.1%), or (5.8%) in constant currency, primarily driven by lower sales of mammography capital equipment, as expected. This decline was partially offset by the inclusion of Endomagnetics revenue and increased service contract revenue.
  • Organic breast health revenue, which excludes sales from the divested SSI and acquired Endomagnetics businesses, decreased (10.1%), or (10.8%) in constant currency.
• Surgical revenue of $178.4 million grew 7.1%, or 6.3% in constant currency, primarily driven by the acquired Gynesonics business and strong international sales.
  • Organic surgical revenue, which excludes sales from Gynesonics, increased 2.0%, or 1.2% in constant currency.
• Cash flow from operations was a strong $343.2 million in the third quarter.
• The Company refinanced its term loan and revolving credit facility in July. The facility now comprises a $1.17 billion term loan and a $1.25 billion revolver, and matures in July 2030.

Key financial results for the fiscal third quarter are shown in the table below.